A GSH-responsive nanophotosensitizer for efficient photodynamic therapy

Functionalized nanozyme with drug loading for enhanced tumour combination treatment of catalytic therapy and chemotherapy

Nanozyme-based tumour catalytic therapy has attracted widespread attention in recent years, but the therapeutic efficacy is limited due to the trapping of hydroxyl radicals (˙OH) by endogenous glutathione (GSH) in the tumour microenvironment (TME). Zr/Ce-MOFs/DOX/MnO2 is constructed in this work to serve as a new kind of nanozyme for combination chemotherapy and catalytic treatment. Zr/Ce-MOFs can produce ˙OH in a mimic TME, and the MnO2 on the surface could deplete the GSH, further promoting the ˙OH generation. The pH/GSH dual stimulation accelerates the release of anticancer drug doxorubicin (DOX) in tumour tissue for enhanced tumour chemotherapy. Moreover, Mn2+ produced by the reaction of Zr/Ce-MOFs/DOX/MnO2 and GSH can be used as the contrast agent for T1-MRI. The potential antitumour effect of Zr/Ce-MOFs/DOX/MnO2 is demonstrated by in vitro and in vivo cancer treatment tests. This work thus provides a new nanozyme-based platform for enhanced combination chemotherapy and catalytic treatment for tumours.

Orthogonal Optimization, Characterization, and In Vitro Anticancer Activity Evaluation of a Hydrogen Peroxide-Responsive and Oxygen-Reserving Nanoemulsion for Hypoxic Tumor Photodynamic Therapy

Tumor hypoxia can seriously impede the effectiveness of photodynamic therapy (PDT). To address this issue, two approaches, termed in situ oxygen generation and oxygen delivery, were developed. The in situ oxygen generation method uses catalysts such as catalase to decompose excess H₂O₂ produced by tumors. It offers specificity for tumors, but its effectiveness is limited by the low H₂O₂ concentration often present in tumors. The oxygen delivery strategy relies on the high oxygen solubility of perfluorocarbon, etc., to transport oxygen. It is effective, but lacks tumor specificity. In an effort to integrate the merits of the two approaches, we designed a multifunctional nanoemulsion system named CCIPN and prepared it using a sonication-phase inversion composition-sonication method with orthogonal optimization. CCIPN included catalase, the methyl ester of 2-cyano-3,12-dioxooleana-1,9(11)-dien-28-oic acid (CDDO-Me), photosensitizer IR780, and perfluoropolyether. Perfluoropolyether may reserve the oxygen generated by catalase within the same nanoformulation for PDT. CCIPN contained spherical droplets below 100 nm and showed reasonable cytocompatibility. It presented a stronger ability to generate cytotoxic reactive oxygen species and consequently destroy tumor cells upon light irradiation, in comparison with its counterpart without catalase or perfluoropolyether. This study contributes to the design and preparation of oxygen-supplementing PDT nanomaterials.

A novel heptamethine cyanine photosensitizer for FRET-amplified photodynamic therapy and two-photon imaging in A-549 cells

In this study, a new cyanine-based photosensitizer Cy-N-Rh was developed for photodynamic therapy. Based on fluorescence resonance energy transfer (FRET) mechanism, utilizing the absorption of the donor rhodamine (Rh), the acceptor heptamethine cyanine unit (Cy) was indirectly excited to produce singlet oxygen (¹O₂). The efficiency of energy transfer from the donor Rh to the acceptor Cy was 78.5%. Meanwhile, the singlet oxygen yield of Cy-N-Rh (Φ_Δ = 12.00%) was much higher than that of the acceptor Cy (Φ_Δ = 4.35%) without FRET. Moreover, the dual cation gave Cy-N-Rh with excellent mitochondria-targeting ability with Pearson's correlation coefficients of 0.90 and 0.91, respectively. In the MTT test, Cy-N-Rh had low dark cytotoxicity with cell survival rate above 90% and high photo cytotoxicity with cell survival rate below 40%. The cell apoptosis assay also demonstrated the role of the photosensitizer Cy-N-R visually. More importantly, Cy-N-Rh fulfilled two-photon excitation fluorescence imaging under the 800 nm femtosecond laser. All results indicate that this design strategy provides a new method for the development of higher-level cyanine photosensitizers.

Dynamic nano-assemblies based on two-dimensional inorganic nanoparticles: Construction and preclinical demonstration

Dynamic drug delivery systems (DDSs) have the ability of transforming their morphology and functionality in response to the biological microenvironments at the disease site and/or external stimuli, show spatio-temporally controllable drug delivery, and enhance the treatment efficacy. Due to the large surface area and modification flexibility, two-dimensional (2D) inorganic nanomaterials are being increasingly exploited for developing intelligent DDSs for biomedical applications. In this review, we summarize the engineering methodologies used to construct transformable 2D DDSs, including changing compositions, creating defects, and surface dot-coating with polymers, biomolecules, or nanodots. Then we present and discuss dynamic inorganic 2D DDSs whose transformation is driven by the diseased characteristics, such as pH gradient, redox, hypoxia, and enzyme in the tumor microenvironment as well as the external stimuli including light, magnetism, and ultrasound. Finally, the limitations and challenges of current transformable inorganic DDSs for clinical translation and their in vivo safety assessment are discussed.

Overcoming barriers in photodynamic therapy harnessing nano-formulation strategies

Photodynamic therapy (PDT) has been extensively investigated for decades for tumor treatment because of its non-invasiveness, spatiotemporal selectivity, lower side-effects, and immune activation ability. It can be a promising treatment modality in several medical fields, including oncology, immunology, urology, dermatology, ophthalmology, cardiology, pneumology, and dentistry. Nevertheless, the clinical application of PDT is largely restricted by the drawbacks of traditional photosensitizers, limited tissue penetrability of light, inefficient induction of tumor cell death, tumor resistance to the therapy, and the severe pain induced by the therapy. Recently, various photosensitizer formulations and therapy strategies have been developed to overcome these barriers. Significantly, the introduction of nanomaterials in PDT, as carriers or photosensitizers, may overcome the drawbacks of traditional photosensitizers. Based on this, nanocomposites excited by various light sources are applied in the PDT of deep-seated tumors. Modulation of cell death pathways with co-delivered reagents promotes PDT induced tumor cell death. Relief of tumor resistance to PDT with combined therapy strategies further promotes tumor inhibition. Also, the optimization of photosensitizer formulations and therapy procedures reduces pain in PDT. Here, a systematic summary of recent advances in the fabrication of photosensitizers and the design of therapy strategies to overcome barriers in PDT is presented. Several aspects important for the clinical application of PDT in cancer treatment are also discussed.

Inorganic nanomaterials with rapid clearance for biomedical applications

Inorganic nanomaterials that have inherently exceptional physicochemical properties (e.g., catalytic, optical, thermal, electrical, or magnetic performance) that can provide desirable functionality (e.g., drug delivery, diagnostics, imaging, or therapy) have considerable potential for application in the field of biomedicine. However, toxicity can be caused by the long-term, non-specific accumulation of these inorganic nanomaterials in healthy tissues, preventing their large-scale clinical utilization. Over the past several decades, the emergence of biodegradable and clearable inorganic nanomaterials has offered the potential to prevent such long-term toxicity. In addition, a comprehensive understanding of the design of such nanomaterials and their metabolic pathways within the body is essential for enabling the expansion of theranostic applications for various diseases and advancing clinical trials. Thus, it is of critical importance to develop biodegradable and clearable inorganic nanomaterials for biomedical applications. This review systematically summarizes the recent progress of biodegradable and clearable inorganic nanomaterials, particularly for application in cancer theranostics and other disease therapies. The future prospects and opportunities in this rapidly growing biomedical field are also discussed. We believe that this timely and comprehensive review will stimulate and guide additional in-depth studies in the area of inorganic nanomedicine, as rapid in vivo clearance and degradation is likely to be a prerequisite for the future clinical translation of inorganic nanomaterials with unique properties and functionality.

Near-Infrared Excited Orthogonal Emissive Upconversion Nanoparticles for Imaging-Guided On-Demand Therapy

Photodynamic therapy (PDT) has been considered as a promising and noninvasive strategy for clinical cancer treatment. Nonetheless, building a smart "off-on" theranostic PDT platform to spatiotemporally control the generation of reactive oxygen species in the PDT treatment still remains challenging. Here, we have rationally developed photoswitching upconversion nanoparticles (UCNPs) with orthogonal emissive properties in response to two distinct near-infrared (NIR) emissions at 808 and 980 nm, i.e., red emission with 980 nm excitation and green emission with 808 nm excitation. Unlike traditional photoswitching UCNPs, these specially designed core-shell-shell structured UCNPs do not require complicated multilayer doping as their red and green upconversion luminescence both originate from the same activator Er³⁺ ions in the core structure. As a proof of concept, we have demonstrated the capability of these orthogonal emissive UCNPs for imaging-guided PDT in a real-time manner, where the red emission excited by 980 nm light is used to trigger PDT and the green emission with 808 nm excitation is to diagnose and monitor the therapeutic treatment. Our study suggests that such specially designed UCNPs with orthogonal emissions hold great promise for NIR light-targeted and imaging-guided therapy under precisely spatiotemporal control.